InflaRx N.V. (IFRX) Form 6-K — Oct 22, 2026
InflaRx N.V. (Nasdaq: IFRX) presented new pre-clinical data on izicopan, its oral C5aR1 inhibitor, at the American Society of Nephrology's Kidney Week 2026 in Denver. In two hamster models of kidney injury, oral izicopan significantly attenuated renal injury compared to vehicle controls, including significant reductions in creatinine and BUN (p < 0.001) in the ischemia-reperfusion model. Structural modeling suggests izicopan preserves high-affinity C5aR1 binding while its trifluoromethyl substituent reduces CYP3A4/5 interaction versus avacopan, supporting a differentiated, potentially best-in-class profile with lower drug-drug interaction liability.
Key figures
- Uuo dosing
- once daily for 14 days
- Iri model dose
- 100 mg/kg single oral dose
- Multiple dose range
- 30 mg once daily to 90 mg twice daily for 14 days
- C5a neutrophil blockade
- ≥90% over 14-day dosing period
- Iri creatinine bun pvalue
- p < 0.001
- First in human single dose range
- 3 mg to 240 mg
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.